[Impact of dapagliflozin on cardiovascular risk factors. Beyond glycemic control].
Impacto de dapagliflozina en los factores de riesgo cardiovascular. Más allá del control de la glucemia.
Blood pressure
Dapagliflozin
Dapagliflozina
Diabetes
Inhibidores SGLT2
Peso
Presión arterial
SGLT2 inhibitors
Weight
Journal
Semergen
ISSN: 1578-8865
Titre abrégé: Semergen
Pays: Spain
ID NLM: 9610769
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
23
06
2021
revised:
18
08
2021
accepted:
04
09
2021
pubmed:
16
11
2021
medline:
15
12
2021
entrez:
15
11
2021
Statut:
ppublish
Résumé
Sodium-glucose transport protein 2 (SGLT2) inhibitors are a new class of oral hypoglycemic agents that increase urinary glucose excretion independently of insulin secretion, although an apparently simple mechanism, but with multiple metabolic effects. Dapagliflozin was the first SGLT2 inhibitor marketed in Europe in 2012 for the treatment of patients with type 2 diabetes, and consequently, with the greatest clinical experience. The results of different clinical trials and real-life studies have demonstrated its effectiveness in glycemic control, as they reduce glycosylated hemoglobin, while achieving a decrease in body weight and blood pressure, among others, providing a comprehensive metabolic protection.
Identifiants
pubmed: 34776344
pii: S1138-3593(21)00289-6
doi: 10.1016/j.semerg.2021.09.009
pii:
doi:
Substances chimiques
Benzhydryl Compounds
0
Glucosides
0
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
dapagliflozin
1ULL0QJ8UC
Types de publication
Journal Article
Langues
spa
Sous-ensembles de citation
IM
Pagination
1-4Informations de copyright
Copyright © 2021 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved.